Approximately half of children with acute myeloid leukemia (AML) eventually succumb to their disease. The long-term objective of the proposed research is to improve the clinical management of these patients (and hence their outcome) through sensitive identification of minimal residual disease (MRD) and tracking of leukemia stem cells. A flow cytometric method developed in the applicant's laboratory can distinguish 1 leukemic myeloid cell among 1000 or more normal hematopoietic cells and, in preliminary studies, was successfully applied in monitoring MRD in 85% of children with AML. A positive MRD finding after remission induction was the most powerful predictor of treatment failure.The studies proposed in this application are grounded in a multi-institutional study of AML, which specifies sequential MRD examinations in bone marrow and peripheral blood in approximately 200 children with newly diagnosed AML.
Aim 1 is to extend sensitive MRD monitoring (i.e., 1 AML cell in 10,000 or more normal cells) to all children with AML by identifying novel leukemic cell markers. The proposed strategy relies on comparison of the gene expression profiles of AML cells (150 cases already studied) with those of normal immature myeloid counterparts to identify genes differentially expressed in AML. MRD detection by the newly identified markers will be tested against standard flow cytometric and molecular MRD assays. There is mounting evidence that AML is driven by a distinct subset of transformed hematopoietic stem cells, which are likely to be the most relevant targets for effective AML therapy. However, the clinical significance of leukemia stem cells in AML has not yet been systematically addressed. Thus, studies in Aim 2 will rely on newly-developed flow cytometric methods and on leukemia cell growth assays in vitro and in vivo to establish the prevalence of AML stem cells at diagnosis and determine the prognostic impact of their persistence.
Aim 3 seeks to assess the clinical utility of MRD assay applied to peripheral blood instead of bone marrow. Based on preliminary results, the expectation is that improvements in the sensitivity of MRD assays will allow MRD to be identified in the peripheral blood of most if not all patients with bone marrow MRD, enhancing the prospects for more frequent MRD monitoring in children with AML. Studies in this aim will determine whether higher levels of blood MRD and of circulating leukemic stem cells correlate with a higher risk of relapse.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA115422-05
Application #
7808832
Study Section
Special Emphasis Panel (ZRG1-ONC-T (03))
Program Officer
Merritt, William D
Project Start
2006-06-01
Project End
2011-10-30
Budget Start
2010-05-01
Budget End
2011-10-30
Support Year
5
Fiscal Year
2010
Total Cost
$260,597
Indirect Cost
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Rubnitz, Jeffrey E; Inaba, Hiroto; Kang, Guolian et al. (2015) Natural killer cell therapy in children with relapsed leukemia. Pediatr Blood Cancer 62:1468-72
Inaba, Hiroto; Bhojwani, Deepa; Pauley, Jennifer L et al. (2012) Combination chemotherapy with clofarabine, cyclophosphamide, and etoposide in children with refractory or relapsed haematological malignancies. Br J Haematol 156:275-9
Inaba, Hiroto; Coustan-Smith, Elaine; Cao, Xueyuan et al. (2012) Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia. J Clin Oncol 30:3625-32
Leung, Wing; Pui, Ching-Hon; Coustan-Smith, Elaine et al. (2012) Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. Blood 120:468-72
Leung, Wing; Campana, Dario; Yang, Jie et al. (2011) High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia. Blood 118:223-30
Rubnitz, Jeffrey E; Inaba, Hiroto; Dahl, Gary et al. (2010) Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol 11:543-52
Campana, Dario (2010) Progress of minimal residual disease studies in childhood acute leukemia. Curr Hematol Malig Rep 5:169-76
Shook, David; Coustan-Smith, Elaine; Ribeiro, Raul C et al. (2009) Minimal residual disease quantitation in acute myeloid leukemia. Clin Lymphoma Myeloma 9 Suppl 3:S281-5
Pounds, Stan; Cheng, Cheng; Mullighan, Charles et al. (2009) Reference alignment of SNP microarray signals for copy number analysis of tumors. Bioinformatics 25:315-21
Pounds, Stan; Rai, Shesh N (2009) Assumption Adequacy Averaging as a Concept to Develop More Robust Methods for Differential Gene Expression Analysis. Comput Stat Data Anal 53:1604-1612

Showing the most recent 10 out of 14 publications